Validation and structural characterization of the LEDGF/p75-MLL interface as a new target for the treatment of MLL-dependent leukemia

Cancer Research

Volumn 74, Issue 18, 2014, Pages 5139-5151

  Čermaková, Kateřina ^a   Tesina, Petr ^b,c   Demeulemeester, Jonas ^a   El Ashkar, Sara ^a   Méreau, Hélène ^d   Schwaller, Juerg ^d   Řezáčová, Pavlína ^b,e   Veverka, Vaclav ^b   De Rijck, Jan ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE LYSINE METHYLTRANSFERASE; INTEGRASE; LENS EPITHELIUM-DERIVED GROWTH FACTOR; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; MLL PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN BINDING; SIGNAL PEPTIDE;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANIMALS; BINDING SITES; HISTONE-LYSINE N-METHYLTRANSFERASE; HIV INTEGRASE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MAGNETIC RESONANCE SPECTROSCOPY; MCF-7 CELLS; MICE; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PROTEIN BINDING;

EID: 84907482290     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3602     Document Type: Article

References (50)

1. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007;7:823-33.
2. Jude CD, Climer L, Xu D, Artinger E, Fisher JK, Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007;1:324-37.
3. McMahon KA, Hiew SY, Hadjur S, Veiga-Fernandes H, Menzel U, Price AJ, et al. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007;1:338-45.
4. Meyer C, Hofmann J, Burmeister T, Groger D, Park TS, Emerenciano M, et al. The MLL recombinome of acute leukemias in 2013. Leukemia 2013;27:2165-76.
5. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L, et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010;37:429-37.
6. Bursen A, Schwabe K, Ruster B, Henschler R, Ruthardt M, Dingermann T, et al. The AF4. MLL fusion protein is capable of inducing ALL in mice without requirement of MLL. AF4. Blood 2010;115:3570-9.
7. Emerenciano M, Kowarz E, Karl K, de Almeida Lopes B, Scholz B, Bracharz S, et al. Functional analysis of the two reciprocal fusion genes MLL-NEBL and NEBL-MLL reveal their oncogenic potential. Cancer Lett 2013;332:30-4.
8. Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, et al. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010;17:148-59.
9. Risner LE, Kuntimaddi A, Lokken AA, Achille NJ, Birch NW, Schoenfelt K, et al. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia. J Biol Chem 2013;288:29901-10.
10. Grembecka J, Belcher AM, Hartley T, Cierpicki T. Molecular basis of the mixed lineage leukemia-menin interaction: implications for targeting mixed lineage leukemias. J Biol Chem 2010;285:40690-8.
11. Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML. The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 2005;123:207-18.
12. Yokoyama A, Cleary ML. Menin critically links MLL proteinswith LEDGF on cancer-associated target genes. Cancer Cell 2008;14:36-46.
13. De Rijck J, Bartholomeeusen K, Ceulemans H, Debyser Z, Gijsbers R. High-resolution profiling of the LEDGF/p75 chromatin interaction in the ENCODE region. Nucleic Acids Res 2010;38:6135-47.
14. Eidahl JO, Crowe BL, North JA, McKee CJ, Shkriabai N, Feng L, et al. Structural basis for high-affinity binding of LEDGF PWWP to mononucleosomes. Nucleic Acids Res 2013;41:3924-36.
15. Pradeepa MM, Sutherland HG, Ule J, Grimes GR, Bickmore WA. Psip1/Ledgf p52 binds methylated histone H3K36 and splicing factors and contributes to the regulation of alternative splicing. PLoS Genet 2012;8:e1002717.
16. Bartholomeeusen K, Christ F, Hendrix J, Rain JC, Emiliani S, Benarous R, et al. Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of PogZ. J Biol Chem 2009;284:11467-77.
17. Bartholomeeusen K, De Rijck J, Busschots K, Desender L, Gijsbers R, Emiliani S, et al. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. J Mol Biol 2007;372:407-21.
18. Cherepanov P, Maertens G, Proost P, Devreese B, Van Beeumen J, Engelborghs Y, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003;278:372-81.
19. Maertens G, Cherepanov P, Pluymers W, Busschots K, De Clercq E, D7ebyser Z, et al. LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003;278:33528-39.
20. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, et al. An essential role for LEDGF/p75 in HIV integration. Science 2006;314:461-4.
21. Schrijvers R, De Rijck J, Demeulemeester J, Adachi N, Vets S, Ronen K, et al. LEDGF/p75-independent HIV-1 replication demonstrates a role for HRP-2 and remains sensitive to inhibition by LEDGINs. PLoS Pathog 2012;8:e1002558.
22. Shun MC, Raghavendra NK, Vandegraaff N, Daigle JE, Hughes S, Kellam P, et al. LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. Genes Dev 2007;21:1767-78.
23. Mereau H, De Rijck J, Cermakova K, Kutz A, Juge S, Demeulemeester J, et al. Impairing MLL-fusion gene-mediated transformation by dissecting critical interactions with the lens epithelium-derived growth factor (LEDGF/p75). Leukemia 2013;27:1245-53.
24. Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat Chem Biol 2012;8:277-84.
25. Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, et al. The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 2012;482:542-6.
26. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A 2005;102:17308-13.
27. Desimmie BA, Humbert M, Lescrinier E, Hendrix J, Vets S, Gijsbers R, et al. Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. Mol Ther 2012;20:2064-75.
28. Liu T, Jankovic D, Brault L, Ehret S, Baty F, Stavropoulou V, et al. Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia. Leukemia 2010;24:601-12.
29. Ibrahimi A, Vande Velde G, Reumers V, Toelen J, Thiry I, Vandeputte C, et al. Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. Hum Gene Ther 2009;20:845-60.
30. Schwaller J, Frantsve J, Aster J, Williams IR, Tomasson MH, Ross TS, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J 1998;17:5321-33.
31. Renshaw PS, Veverka V, Kelly G, Frenkiel TA, Williamson RA, Gordon SV, et al. Sequence-specific assignment and secondary structure determination of the 195-residue complex formed by the Mycobacterium tuberculosis proteins CFP-10 and ESAT-6. J Biomol NMR 2004;30:225-6.
32. Veverka V, Lennie G, Crabbe T, Bird I, Taylor RJ, Carr MD. NMR assignment of the mTOR domain responsible for rapamycin binding. J Biomol NMR 2006;36:3.
33. Cheng X, Veverka V, Radhakrishnan A, Waters LC, Muskett FW, Morgan SH, et al. Structure and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013;288:11771-85.
34. Wilkinson IC, Hall CJ, Veverka V, Shi JY, Muskett FW, Stephens PE, et al. High resolution NMR-based model for the structure of a scFv-IL-1beta complex: potential for NMR as a key tool in therapeutic antibody design and development. J Biol Chem 2009;284:31928-35.
35. Herrmann T, Guntert P, Wuthrich K. Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion angle dynamics algorithm DYANA. J Mol Biol 2002;319:209-27.
36. Shen Y, Delaglio F, Cornilescu G, Bax A. TALOS+: a hybrid method for predicting protein backbone torsion angles from NMR chemical shifts. J Biomol NMR 2009;44:213-23.
37. Doreleijers JF, Sousa da Silva AW, Krieger E, Nabuurs SB, Spronk CA, Stevens TJ, et al. CING: an integrated residue-based structure validation program suite. J Biomol NMR 2012;54:267-83.
38. Cherepanov P, Sun ZY, Rahman S, Maertens G, Wagner G, Engelman A. Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75. Nat Struct Mol Biol 2005;12:526-32.
39. Harjes E, Harjes S, Wohlgemuth S, Muller KH, Krieger E, Herrmann C, et al. GTP-Ras disrupts the intramolecular complex of C1 and RA domains of Nore1. Structure 2006;14:881-8.
40. MOE. Molecular Operating Environment. Montreal, QC, Canada: Chemical Computing Group Inc.; 2012.
41. Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009;113:2375-85.
42. Mohan M, Lin C, Guest E, Shilatifard A. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10:721-8.
43. Okada Y, Feng Q, Lin Y, Jiang Q, Li Y, Coffield VM, et al. hDOT1L links histone methylation to leukemogenesis. Cell 2005;121:167-78.
44. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV, et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011;20:66-78.
45. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011;20:53-65.
46. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, et al. Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999;96:143-52.
47. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010;6:442-8.
48. Cavalluzzo C, Christ F, Voet A, Sharma A, Singh BK, Zhang KY, et al. Identification of small peptides inhibiting the integrase-LEDGF/p75 interaction through targeting the cellular co-factor. J Pept Sci 2013;19:651-8.
49. Artinger EL, Mishra BP, Zaffuto KM, Li BE, Chung EK, Moore AW, et al. An MLL-dependent network sustains hematopoiesis. Proc Natl Acad Sci U S A 2013;110:12000-5.
50. Sutherland HG, Newton K, Brownstein DG, Holmes MC, Kress C, Semple CA, et al. Disruption of Ledgf/Psip1 results in perinatal mortality and homeotic skeletal transformations. Mol Cell Biol 2006;26:7201-10.